MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- DIVIS LABORATORIES - GSK PHARMA
DIVIS LABORATORIES vs GSK PHARMA - Comparison Results
DIVIS LABORATORIES Change
Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More
GSK PHARMA 
GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More
Current Valuations
| DIVIS LABORATORIES | GSK PHARMA | DIVIS LABORATORIES/ GSK PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 59.8 | -82.7 | - | View Chart |
| P/BV | x | 13.8 | 12.3 | 111.9% | View Chart |
| Dividend Yield | % | 0.4 | 1.3 | 34.5% |
Financials
 DIVIS LABORATORIES  GSK PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DIVIS LABORATORIES Mar-19 |
GSK PHARMA Mar-19 |
DIVIS LABORATORIES/ GSK PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,639 | 3,595 | 45.6% | |
| Low | Rs | 1,115 | 1,253 | 89.0% | |
| Sales per share (Unadj.) | Rs | 186.3 | 184.7 | 100.9% | |
| Earnings per share (Unadj.) | Rs | 51.0 | 26.3 | 193.8% | |
| Cash flow per share (Unadj.) | Rs | 57.3 | 29.2 | 196.6% | |
| Dividends per share (Unadj.) | Rs | 16.00 | 20.00 | 80.0% | |
| Dividend yield (eoy) | % | 1.2 | 0.8 | 140.8% | |
| Book value per share (Unadj.) | Rs | 261.8 | 126.3 | 207.2% | |
| Shares outstanding (eoy) | m | 265.47 | 169.40 | 156.7% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 7.4 | 13.1 | 56.3% | |
| Avg P/E ratio | x | 27.0 | 92.2 | 29.3% | |
| P/CF ratio (eoy) | x | 24.0 | 83.1 | 28.9% | |
| Price / Book Value ratio | x | 5.3 | 19.2 | 27.4% | |
| Dividend payout | % | 31.4 | 76.1 | 41.3% | |
| Avg Mkt Cap | Rs m | 365,592 | 410,626 | 89.0% | |
| No. of employees | `000 | 11.8 | 5.0 | 238.9% | |
| Total wages/salary | Rs m | 5,423 | 5,372 | 100.9% | |
| Avg. sales/employee | Rs Th | 4,175.1 | 6,306.7 | 66.2% | |
| Avg. wages/employee | Rs Th | 457.7 | 1,083.1 | 42.3% | |
| Avg. net profit/employee | Rs Th | 1,141.8 | 898.0 | 127.2% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 49,463 | 31,281 | 158.1% | |
| Other income | Rs m | 1,556 | 1,023 | 152.1% | |
| Total revenues | Rs m | 51,019 | 32,304 | 157.9% | |
| Gross profit | Rs m | 18,718 | 6,009 | 311.5% | |
| Depreciation | Rs m | 1,689 | 486 | 347.5% | |
| Interest | Rs m | 35 | 6 | 583.3% | |
| Profit before tax | Rs m | 18,551 | 6,540 | 283.6% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 287 | 0.0% | |
| Tax | Rs m | 5,023 | 2,373 | 211.7% | |
| Profit after tax | Rs m | 13,527 | 4,454 | 303.7% | |
| Gross profit margin | % | 37.8 | 19.2 | 197.0% | |
| Effective tax rate | % | 27.1 | 36.3 | 74.6% | |
| Net profit margin | % | 27.3 | 14.2 | 192.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 46,501 | 20,061 | 231.8% | |
| Current liabilities | Rs m | 8,468 | 14,543 | 58.2% | |
| Net working cap to sales | % | 76.9 | 17.6 | 435.9% | |
| Current ratio | x | 5.5 | 1.4 | 398.1% | |
| Inventory Days | Days | 131 | 57 | 230.4% | |
| Debtors Days | Days | 86 | 14 | 610.6% | |
| Net fixed assets | Rs m | 25,797 | 14,343 | 179.9% | |
| Share capital | Rs m | 531 | 1,694 | 31.3% | |
| "Free" reserves | Rs m | 68,962 | 19,704 | 350.0% | |
| Net worth | Rs m | 69,493 | 21,398 | 324.8% | |
| Long term debt | Rs m | 0 | 2 | 0.0% | |
| Total assets | Rs m | 80,383 | 39,113 | 205.5% | |
| Interest coverage | x | 531.0 | 1,091.0 | 48.7% | |
| Debt to equity ratio | x | 0 | 0 | 0.0% | |
| Sales to assets ratio | x | 0.6 | 0.8 | 76.9% | |
| Return on assets | % | 16.9 | 11.4 | 148.0% | |
| Return on equity | % | 19.5 | 20.8 | 93.5% | |
| Return on capital | % | 26.7 | 31.9 | 83.8% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 24.6 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | 12,187 | NA | - | |
| Fx inflow | Rs m | 41,238 | 534 | 7,722.4% | |
| Fx outflow | Rs m | 12,405 | 7,091 | 174.9% | |
| Net fx | Rs m | 28,833 | -6,557 | -439.7% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 9,543 | 3,994 | 238.9% | |
| From Investments | Rs m | -6,854 | -1,433 | 478.2% | |
| From Financial Activity | Rs m | -2,459 | -3,584 | 68.6% | |
| Net Cashflow | Rs m | 230 | -1,023 | -22.4% | |
Share Holding
| Indian Promoters | % | 52.0 | 0.0 | - | |
| Foreign collaborators | % | 0.0 | 50.7 | - | |
| Indian inst/Mut Fund | % | 11.8 | 10.2 | 115.7% | |
| FIIs | % | 19.0 | 23.8 | 79.8% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 17.2 | 15.4 | 111.7% | |
| Shareholders | 31,796 | 102,036 | 31.2% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare DIVIS LABORATORIES With: NATCO PHARMA FRESENIUS KABI ONCO. FDC. TORRENT PHARMA STRIDES PHARMA SCIENCE
Compare DIVIS LABORATORIES With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
Sensex Ends 110 Points Lower; Smallcap & Midcap Stocks Outperform(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower, ahead of Q2 GDP data.
Related Views on News
GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)
Oct 30, 2020 | Updated on Oct 30, 2020For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)
Aug 26, 2020 | Updated on Aug 26, 2020For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)
Aug 10, 2020 | Updated on Aug 10, 2020For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)
Jun 8, 2020 | Updated on Jun 8, 2020For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)
Feb 6, 2020 | Updated on Feb 6, 2020For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
More Views on NewsMost Popular
Not Infosys or Wipro. India's Next Wealth Creators Could Be Drone Stocks(Profit Hunter)
Nov 25, 2020India's drones directorate signals the next big defence tech multibaggers.
Stocks that Could Shine More than Gold After Diwali(Profit Hunter)
Nov 17, 2020If the markets become volatile over the next few months, do this.
It's Time to Book Profits(Fast Profits Daily)
Nov 27, 2020In my first video on Equitymaster, I want to introduce you my proprietary greed and fear index. It's telling us to book some profits in the market.
How the New Margins Will Impact You(Fast Profits Daily)
Nov 25, 2020The new rules on margins will come into effect from 1st December. Are you ready?
An Eraser and Some Pencils(The Honest Truth)
Nov 17, 2020Ajit Dayal on the road ahead for the world after covid.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
DIVIS LABORATORIES SHARE PRICE
Nov 27, 2020 (Close)
TRACK DIVIS LABORATORIES
- Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DIVIS LABORATORIES
DIVIS LABORATORIES 8-QTR ANALYSIS
COMPARE DIVIS LABORATORIES WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.